Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 0.42 below Cellectis S A 's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 140 other companies have achieved higher Quick Ratio than Cellectis S A in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 3127.

Explain Quick Ratio?
How much Cash & cash equivalents CLLS�s has?
What are CLLS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CLLS Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	-12.34 %	-12.34 %	-12.55 %	-12.34 %	9455.69 %
Y / Y Cash & cash equivalent Change	-57.05 %	-57.05 %	-59.87 %	-57.05 %	4.79 %
Quick Ratio MRQ	0.42	0.42	0.41	0.42	0.86
CLLS's Total Ranking	# 3127	# 0	#	#	#
Seq. Current Liabilities Change	0 %	0.2 %	-0.2 %	-12.34 %	0 %
Seq. Cash & cash equivalent Change	0 %	2.88 %	-2.8 %	-57.05 %	0 %

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 141
Healthcare Sector	# 833
Overall Market	# 3127

Quick Ratio Statistics
High	Average	Low
428.57	36.65	0.41
(Dec 31 2016)		0

Financial Statements
Cellectis S A 's Current Liabilities	$ 146 Millions	Visit CLLS's Balance sheet
Cellectis S A 's Cash & cash equivalent	$ 62 Millions	Visit CLLS's Balance sheet
Source of CLLS's Sales		Visit CLLS's Sales by Geography

Cumulative Cellectis S A 's Quick Ratio

CLLS's Quick Ratio for the trailling 12 Months

CLLS Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-12.39 %	20.5 %	86.56 %	281.34 %	1206.74 %
Y / Y Cash & cash equivalent TTM Growth	-57.77 %	-43.01 %	-4.93 %	36.43 %	75.83 %
Quick Ratio TTM	0.42	0.54	0.65	0.77	0.87
Total Ranking TTM	# 4658	# 0	#	#	#
Seq. Current Liabilities TTM Growth	-3.4 %	-3.29 %	-3.24 %	-3.08 %	32.87 %
Seq. Cash & cash equivalent TTM Growth	-25.06 %	-20.04 %	-17.95 %	-14.12 %	1.14 %

Quick ratio ranking by company, industry and sector >> Back to CLLS Financial Strength Comparisons >> Go to Compare CLLS Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in CLLS's Current Liabilities to $145.75 millions, cumulative Quick Ratio to 0.42 below the CLLS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 157 other companies have achieved higher Quick Ratio than Cellectis S A . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 4658.

Explain Quick Ratio?
How much Cash & cash equivalents CLLS�s has?
What are CLLS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 158
Healthcare Sector	# 992
Within the Market	# 4658

trailing twelve months Quick Ratio Statistics
High	Average	Low
9.63	3.64	0.4
(Dec 31 2018)		(Dec 31 2025)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Alvotech	1.06	$ 172.359 Millions	$ 163.045 Millions
Biocardia Inc	1.03	$ 2.496 Millions	$ 2.432 Millions
Tradeup Acquisition Corp	1.00	$ 1.384 Millions	$ 1.388 Millions
Bio techne Corp	0.92	$ 162.186 Millions	$ 175.849 Millions
Ocugen Inc	0.81	$ 18.571 Millions	$ 23.043 Millions
Quince Therapeutics Inc	0.79	$ 34.097 Millions	$ 43.226 Millions
Scinai Immunotherapeutics Ltd	0.78	$ 1.661 Millions	$ 2.116 Millions
Innate Pharma Sa	0.77	$ 31.463 Millions	$ 41.047 Millions
Halozyme Therapeutics Inc	0.76	$ 133.820 Millions	$ 177.092 Millions
Pelthos Therapeutics Inc	0.69	$ 17.973 Millions	$ 25.993 Millions
Pluri Inc	0.64	$ 20.613 Millions	$ 32.328 Millions
Valneva Se	0.63	$ 122.808 Millions	$ 193.672 Millions
Protalix Biotherapeutics inc	0.58	$ 15.382 Millions	$ 26.518 Millions
Xtant Medical Holdings Inc	0.58	$ 17.053 Millions	$ 29.484 Millions
Atara Biotherapeutics Inc	0.57	$ 8.482 Millions	$ 14.922 Millions
Meiragtx Holdings Plc	0.54	$ 65.931 Millions	$ 122.555 Millions
Surrozen Inc	0.53	$ 89.245 Millions	$ 167.302 Millions
Aim Immunotech Inc	0.51	$ 3.047 Millions	$ 5.974 Millions
Sangamo Therapeutics Inc	0.49	$ 20.948 Millions	$ 42.466 Millions
Aptose Biosciences Inc	0.45	$ 4.096 Millions	$ 9.113 Millions
Cellectis S a	0.42	$ 61.533 Millions	$ 145.752 Millions
Curis Inc	0.39	$ 5.061 Millions	$ 12.886 Millions
Amgen Inc	0.36	$ 9,129.000 Millions	$ 25,489.000 Millions
Bioatla Inc	0.32	$ 7.118 Millions	$ 22.583 Millions
Eloxx Pharmaceuticals Inc	0.28	$ 4.785 Millions	$ 17.177 Millions
Biogen Inc	0.24	$ 807.200 Millions	$ 3,349.400 Millions
Phoenix Biotech Acquisition Corp	0.20	$ 1.700 Millions	$ 8.514 Millions
Outlook Therapeutics Inc	0.18	$ 8.083 Millions	$ 45.756 Millions
ADAPTIN BIO, INC.	0.17	$ 0.459 Millions	$ 2.772 Millions
Viskase Holdings inc	0.13	$ 9.217 Millions	$ 68.624 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.